APPENDIX A TO APPENDIX C 
and a Certification Statement (Certification) from the institu- 
tional biohazards committee. The NIH must and will require that 
a properly executed MUA and Certification accompany all appli- 
cations proposing to use recombinant DNA technology. This will 
eliminate the need for tracking these documents after the 
application is accepted for review. The originals of these 
documents will be placed in the official files of the NIH award- 
ing components with copies on file in ORDA. 
Review of Applications 
The executive secretaries of initial review groups are respon- 
sible for identifying all applications involving recombinant 
DNA technology, and for placing on the first page of every 
sumnary statement the following special note: 
Recombinant DNA Molecules - Potential Biohazard 
The executive secretaries are responsible for ensuring that 
the initial review groups make an independent assessment of 
the biological and physical containment levels required for 
the proposed experiments, and for stating in the text of the 
summary statement the initial review group's determination 
as to whether the containment levels proposed by the investi- 
gator meet the levels stipulated in the NIH guidelines. If 
the proposed containment levels are inadequate, the initial 
review group should discuss, in as much detail as possible, 
the inadequacies of the proposed containment and under what 
circumstances, if at all, the application should be eligible 
for funding. Initial review groups should be encouraged to 
disapprove applications if the proposed containment levels 
are so inadequate as to be irresponsible. It will be the 
responsibility of the awarding unit to inform applicants 
directly as to the fact that this was the reason for dis- 
approval . 
Executive secretaries and members of relevant initial review 
grpups will receive a copy of the Guidelines to permit them 
to make these judgments. Problems relating to assessment of 
biological and physical containment levels proposed by in- 
vestigators versus those required by the Guidelines will be 
referred to ORDA. 
As in the case of human experimentation, national advisory 
councils and boards and final review bodies are expected 
to carefully scrutinize proposals involving recombinant DNA 
technology, and make appropriate recommendations. 
Appendix C — 8 
